After positive results provided by its clinical study evaluating the effects of novel DMT on patients with major depressive disorder (MDD), psychedelics biotech Small Pharma Inc. DMTTF is updating its IP portfolio following the United States Patent and Trademark Office’s (USPTO) notice of approval to file a patent application covering compositions of matter, therapeutic compositions and uses of a group of deuterated DMT compounds.
The USPTO will shortly grant the Company a patent composition of matter for certain deuterated homologues of certain tryptamine compounds, including the active ingredients being tested in the SPL-029 panel of oral tryptamines, and therapeutic compositions of the deuterated tryptamines, including orally active formulations.
Small Pharma’s multi-pronged patent strategy targets key areas of protection across its research and development pipeline.
For SPL026, this includes an optimized injectable formulation for extended shelf life and a synthetic, GMP (Good Manufacturing Process) compliant route. For the pipeline candidate SPL028 and the SPL029 series, this means protecting the material composition of the deuterated compounds as well as their medical use and therapeutic composition.
“Innovation in well-known compounds has always been the foundation of Small Pharma’s vision, and we continue to look for ways to innovate our assets to optimize their clinical and commercial potential,” said CEO George Tziras, who reiterates the company’s commitment , “to develop new scalable products and reimbursable short-term treatment for the mentally ill.”
Tziras added that building a robust IP position is key to protecting these innovations and allowing pipeline programs to work toward developing a proprietary position in key markets like the US and Europe.
Photo: Benzinga edit with photo by CDC…
[ad_2]
Source story
